npce-202306070001528287false00015282872023-06-072023-06-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 7, 2023
NEUROPACE, INC.
(Exact name of registrant as specified in its charter)
| | | | | | | | |
Delaware (State or Other Jurisdiction of Incorporation) | 001-40337 (Commission File Number) | 22-3550230 (IRS Employer Identification No.) |
455 N. Bernardo Avenue Mountain View, CA (Address of principal executive offices) | | 94043 (Zip Code) |
(650) 237-2700
Registrant's telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
| Common Stock, $0.001 par value per share | | NPCE | | Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 7, 2023, NeuroPace, Inc. held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) virtually via live webcast. The following proposals were voted upon, and the final voting results with respect to each such proposal are set forth below:
Proposal 1 - Election of Directors. NeuroPace’s stockholders elected each of the following Class II director nominees to hold office until NeuroPace’s 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, or removal. The results of the vote were:
| | | | | | | | | | | |
| Nominee | For | Withhold | Broker Non-Votes |
| Lisa Andrade | 8,506,611 | 432,292 | 7,538,467 |
| Joseph Lacob | 8,475,094 | 463,809 | 7,538,467 |
Proposal 2 - Ratification of Independent Registered Public Accounting Firm. NeuroPace’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as NeuroPace’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the vote were:
| | | | | | | | | | | |
For | Against | Abstain | Broker Non-Votes |
| 16,456,369 | 9,012 | 11,989 | 0 |
No other matters were submitted for stockholder action at the Annual Meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| NeuroPace, Inc. |
| |
| Dated: June 12, 2023 | By: | /s/ Irina Ridley |
| | Irina Ridley |
| | Chief Legal Officer and Corporate Secretary |